Mizuho Markets Americas LLC Invests $3.94 Million in Teladoc Health, Inc. (NYSE:TDOC)

Mizuho Markets Americas LLC bought a new stake in Teladoc Health, Inc. (NYSE:TDOC - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 402,530 shares of the health services provider's stock, valued at approximately $3,937,000. Mizuho Markets Americas LLC owned approximately 0.24% of Teladoc Health at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider's stock valued at $377,451,000 after purchasing an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP increased its stake in Teladoc Health by 25.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider's stock worth $82,636,000 after acquiring an additional 767,999 shares during the last quarter. Norges Bank purchased a new position in shares of Teladoc Health in the 4th quarter worth about $9,714,000. Pale Fire Capital SE purchased a new stake in shares of Teladoc Health during the 4th quarter worth about $8,960,000. Finally, Natixis grew its stake in Teladoc Health by 106.6% during the first quarter. Natixis now owns 19,898 shares of the health services provider's stock worth $300,000 after buying an additional 319,898 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Stock Performance

TDOC stock traded up $0.07 during mid-day trading on Friday, reaching $7.17. The company had a trading volume of 8,654,028 shares, compared to its average volume of 5,697,169. Teladoc Health, Inc. has a one year low of $6.76 and a one year high of $23.19. The stock has a market capitalization of $1.23 billion, a P/E ratio of -5.09 and a beta of 0.93. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock's 50-day simple moving average is $8.51 and its two-hundred day simple moving average is $11.84.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The firm had revenue of $642.44 million for the quarter, compared to the consensus estimate of $649.34 million. Research analysts anticipate that Teladoc Health, Inc. will post -0.71 EPS for the current year.

Insider Transactions at Teladoc Health

In other news, CEO Laizer Kornwasser sold 10,879 shares of the firm's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $88,555.06. Following the transaction, the chief executive officer now directly owns 99,929 shares of the company's stock, valued at $813,422.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Michael Willem Waters sold 6,053 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $49,271.42. Following the completion of the transaction, the chief operating officer now owns 74,214 shares in the company, valued at approximately $604,101.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the completion of the sale, the chief executive officer now directly owns 99,929 shares of the company's stock, valued at $813,422.06. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,880 shares of company stock worth $355,689. Company insiders own 0.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Bank of America lowered their target price on Teladoc Health from $16.50 to $13.50 and set a "neutral" rating for the company in a research note on Tuesday, May 14th. Barclays reduced their target price on shares of Teladoc Health from $20.00 to $10.00 and set an "overweight" rating on the stock in a research report on Thursday, August 1st. Evercore ISI dropped their price target on shares of Teladoc Health from $14.00 to $10.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 9th. DA Davidson decreased their price objective on shares of Teladoc Health from $12.00 to $8.00 and set a "neutral" rating for the company in a research report on Thursday, August 1st. Finally, Truist Financial dropped their target price on Teladoc Health from $15.00 to $10.00 and set a "hold" rating on the stock in a research report on Friday, August 2nd. Fourteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Teladoc Health presently has an average rating of "Hold" and an average target price of $12.44.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.